Multi-drug resistant Clostridioides difficile isolate ST81 is prominent in hematological patients in a teaching hospital in China
Abstract
INTRODUCTION: Clostridioides difficile Infection (CDI) is more prevalent in people with hematologic diseases. However, epidemiological characteristics are poorly understood.
METHODS: From July 2016 to November 2021, we studied the epidemiology of CDI in patients with hematological diseases at a tertiary teaching hospital in Shanghai, China.
RESULTS: In hematological patients, the prevalence of CDI was 21.6%, with 89.8% hospital-acquired infections. C. difficile ST81, which is a multidrug-resistant strain carrying only the toxin B, is the most common strain (38.1%), followed by ST3 (16.7%) and ST2 (9.5%). Clindamycin and moxifloxacin resistance rates of all C. difficile species were 64.3% and 31%, respectively, and no isolate was resistant to vancomycin, linezolid, metronidazole, teicoplanin, or daptomycin.
DISCUSSION: This study provides a comprehensive characterization of CDI in hematological patients, highlighting the urgent need for enhanced surveillance and preventive strategies against this emerging nosocomial threat.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.